Cerus (CERS) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cerus Corporation Reports Second Quarter 2016 Results
August 4, 2016 4:01 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2016.
Recent developments include:
With confirmation of local Zika cases in Florida, the FDA has advised blood establishments in the affected counties to either cease local blood collections, implement pathogen reduction technology, and/or implement testing via an investigational donor screening test. The Biomedical Advanced Research and Development Authority (BARDA) awarded Cerus a 5-year contract with potential funding of up to $181 million to... More